Literature DB >> 17854602

Eradication therapy for Helicobacter pylori.

Nimish Vakil1, Francis Megraud.   

Abstract

Eradication therapy for Helicobacter pylori is recommended in a number of clinical conditions. In this article, we discuss the epidemiology and cellular mechanisms that result in antimicrobial resistance, the results of current eradication therapies, and new approaches to the management of Helicobacter pylori infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17854602     DOI： 10.1053/j.gastro.2007.07.008

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


  63 in total

1.  Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population.

Authors:  Luigi Gatta; Francesco Di Mario; Dino Vaira; Angelo Franzé; Massimo Rugge; Alberto Pilotto; Paolo Lucarini; Maurizio Lera; Giulia Fiorini; Valentina Castelli; Enkleda Kajo; Carmelo Scarpignato
Journal:  Intern Emerg Med       Date:  2010-08-19       Impact factor: 3.397

2.  Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia.

Authors:  Alba A Trespalacios; William Otero; Jorge E Caminos; Marcela M Mercado; Jenny Avila; Liliana E Rosero; Azucena Arévalo; Raúl A Poutou-Piñales; David Y Graham
Journal:  J Microbiol       Date:  2013-08-30       Impact factor: 3.422

3.  Antibiotics resistance rate of Helicobacter pylori in Bhutan.

Authors:  Ratha-korn Vilaichone; Yoshio Yamaoka; Seiji Shiota; Thawee Ratanachu-ek; Lotay Tshering; Tomohisa Uchida; Toshio Fujioka; Varocha Mahachai
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

4.  Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Wang-Huei Sheng; Yu-Chi Wang; Mei-Jyh Chen; Yi-Chia Lee; Hsu-Wei Hung; Hung Chian; San-Chun Chang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

5.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

6.  The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.

Authors:  Tran T Binh; Seiji Shiota; Lam T Nguyen; Dung D Q Ho; Hai H Hoang; Long Ta; Dung T Trinh; Toshio Fujioka; Yoshio Yamaoka
Journal:  J Clin Gastroenterol       Date:  2013-03       Impact factor: 3.062

7.  Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.

Authors:  Abdallah Said Essa; Jennifer Rosenthal Kramer; David Y Graham; Gerhard Treiber
Journal:  Helicobacter       Date:  2009-04       Impact factor: 5.753

8.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 9.  Eradication of Helicobacter pylori infection: which regimen first?

Authors:  Alessandro Federico; Antonietta Gerarda Gravina; Agnese Miranda; Carmela Loguercio; Marco Romano
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 10.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.